Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential
Vaxcyte Inc PCVX
$54.08
▼ -3.36%
($-1.88)
📅 Earnings This Week
Open
$56.10
Prev Close
$55.96
Day Range
$53.53 – $56.39
52W Range
$29.08 – $65.00
Market Cap
$7.81B
Beta
1.22
EPS (TTM)
$-6.89
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-12 |
| Shares Out. | 144,400,000 |
| Website | vaxcyte.com/ ↗ |
| Phone | 13026587581 |
| Employees | 507 |
| Net Income | -$320.6M |
| Free Cash Flow | -$814.9M |
| Total Assets | $3.35B |
| Total Liabilities | $352.3M |
| Equity | $3.00B |
About Vaxcyte Inc
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Vaxcyte Inc is a publicly traded company under the ticker symbol PCVX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-07-01)